
    
      All eligible patients will be treated with rasburicase 0.20 mg/kg body weight intravenously
      for 4 days. The primary endpoints viz., the percentage of reduction in plasma uric acid at 4
      hrs after uric acid-lowering therapy, plasma uric acid AUC 0-96 hr and incidence of adverse
      events will be assessed during 11 days study period.
    
  